AstraZeneca (LON:AZN) PT Raised to GBX 74 at Jefferies Financial Group

AstraZeneca (LON:AZN) had its price target raised by Jefferies Financial Group from GBX 71 ($0.90) to GBX 74 ($0.94) in a report released on Tuesday, MarketBeat.com reports. Jefferies Financial Group currently has a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on AZN. Berenberg Bank boosted their price target on shares of AstraZeneca from £130 ($164.43) to £150 ($189.73) and gave the company a buy rating in a report on Friday, June 7th. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a report on Tuesday, June 4th. Citigroup restated a buy rating on shares of AstraZeneca in a report on Tuesday, May 28th. Deutsche Bank Aktiengesellschaft restated a hold rating and issued a £110 ($139.13) price target on shares of AstraZeneca in a report on Tuesday, June 18th. Finally, Shore Capital reiterated a buy rating on shares of AstraZeneca in a research note on Tuesday, May 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of £105.53 ($133.49).

AstraZeneca Trading Down 1.8 %

LON:AZN opened at £120.86 ($152.87) on Tuesday. AstraZeneca has a one year low of GBX 9,461 ($119.67) and a one year high of £127.04 ($160.69). The company has a debt-to-equity ratio of 92.51, a quick ratio of 0.59 and a current ratio of 0.89. The firm has a market cap of £187.33 billion, a P/E ratio of 3,873.72, a P/E/G ratio of 0.97 and a beta of 0.16. The firm has a 50-day simple moving average of £122.52 and a 200-day simple moving average of £110.93.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.